Divi's Labs Q2 Review - In-Line; Strong Operating Performance: Dolat Capital
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Divi' s Laboratories Ltd. reported an in-line operating performance in Q2 aided by Molnupiravir sales.
Healthy gross margins at 67% (backward integration coupled with better process technology reduces dependency) and better product mix (generic and custom synthesis contributed 46% and 54% respectively) aided margins at 41%.
Adjusting for forex gain of Rs 71 million, profit after tax came in at Rs 6.1 billion in line with our estimates.
Divi’s Labs reiterated its six key growth engines that would continue to drive 10-15% revenue growth in the medium term with sustained margins.
Capex for the current growth drivers is already in the last stage and progressing well.
Key point to note is that management remains confident on future of generic active pharma ingredients and believes that end-to-end integration coupled with better process technology are its key success levers.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.